Monlunabant
Monlunabant[edit | edit source]
Monlunabant is a synthetic compound that acts as a selective antagonist of the cannabinoid receptor type 1 (CB1). It was developed for potential therapeutic use in the treatment of obesity and related metabolic disorders. Monlunabant is part of a class of drugs known as cannabinoid receptor antagonists, which work by blocking the effects of endogenous cannabinoids in the body.
Mechanism of Action[edit | edit source]
Monlunabant functions by selectively binding to the CB1 receptors, which are primarily located in the central nervous system and peripheral tissues. By blocking these receptors, Monlunabant inhibits the action of endogenous cannabinoids such as anandamide and 2-arachidonoylglycerol, which are involved in the regulation of appetite, mood, and energy balance. This blockade is thought to reduce food intake and promote weight loss, making it a potential treatment for obesity.
Development and Clinical Trials[edit | edit source]
Monlunabant was developed as part of a broader effort to create effective anti-obesity medications. During preclinical studies, it demonstrated the ability to reduce food intake and body weight in animal models. However, like other CB1 antagonists, its development faced challenges due to potential side effects, including mood alterations and psychiatric symptoms.
Potential Therapeutic Uses[edit | edit source]
The primary therapeutic use of Monlunabant was intended to be in the management of obesity. By reducing appetite and promoting weight loss, it was hoped that Monlunabant could help reduce the risk of obesity-related conditions such as type 2 diabetes, cardiovascular disease, and hypertension.
Side Effects and Safety Concerns[edit | edit source]
The use of CB1 antagonists, including Monlunabant, has been associated with several side effects. These can include mood changes, depression, anxiety, and other psychiatric symptoms. The safety profile of Monlunabant was a significant concern during its development, and these potential side effects have limited the clinical use of similar compounds.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
